The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASCO 2024 | Novel agents for the treatment of Hodgkin lymphoma: brentuximab vedotin and nivolumab
Stephen Ansell, MD, PhD, Mayo Clinic, Rochester, MN, highlights exciting developments in Hodgkin lymphoma (HL) treatment, particularly focusing on novel agents brentuximab vedotin and nivolumab. The BrECADD (brentuximab vedotin, etoposide, cyclophosphamide, doxorubicin, dacarbazine, dexamethasone) regimen shows particular promise for the future. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
